Rigel Pharmaceuticals | RIGL - Pre Tax Profit


Rigel Pharmaceuticals reported $-1.03M in Pre-Tax Profit for its fiscal quarter ending in June of 2024.





Pre Tax Profit Change Date
Agenus USD 39.21M 49.82M Mar/2026
Amgen USD 2.08B 570M Mar/2026
Anika Therapeutics USD 764K 3M Dec/2025
Arrowhead Research USD -178.9M 41.34M Jun/2026
AstraZeneca USD 4.81B 894M Jun/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Celldex Therapeutics USD -78.68M 2.63M Mar/2026
Daiichi Sankyo JPY -6.52B 113.25B Mar/2026
Eli Lilly USD 8.85B 583.8M Mar/2026
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Intrexon USD -60.48M 27.09M Jun/2024
Ionis Pharmaceuticals USD -114M 21M Jun/2026
Karyopharm Therapeutics USD -22.39M 17.51M Mar/2026
Ligand Pharmaceuticals USD -24.26M 81.04M Mar/2026
MacroGenics USD -36.77M 21.84M Mar/2026
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Pfizer USD -653M 5.84B Jun/2026
Regeneron Pharmaceuticals USD 1.53B 696.6M Jun/2026
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Ultragenyx Pharmaceutical USD -91M 93M Jun/2026
Veracyte USD 26.52M 3.45M Jun/2026